Maiti, A., DiNardo, C. D., Wang, S. A., Jorgensen, J., Kadia, T. M., Daver, N. G., . . . Ravandi, F. (2021). Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv.
Style de citation ChicagoMaiti, Abhishek, et al. "Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia." Blood Adv 2021.
Style de citation MLAMaiti, Abhishek, et al. "Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia." Blood Adv 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.